Intensity-Modulated Radiation Therapy in Treating Patients With Prostate Cancer

Launched by ROYAL MARSDEN NHS FOUNDATION TRUST · Jul 24, 2009

Keywords

ClinConnect Summary

OBJECTIVES:

* To test the feasibility of delivering hypofractionated intensity-modulated radiotherapy to the prostate and pelvic nodes of patients with prostate cancer.
* To determine the optimal dose level of this treatment regimen to be used in future studies.

OUTLINE: Patients are stratified according to small bowel total volume (low small bowel volume \< 450 cc vs high small bowel volume ≥ 450 cc).

Patients undergo hypofractionated intensity-modulated radiotherapy to the prostate and pelvis for 4 weeks in the absence of disease progression or unacceptable toxicity.

After completion ...

Gender

MALE

Eligibility criteria

• DISEASE CHARACTERISTICS:
• * Diagnosis of prostate cancer meeting 1 of the following criteria:
• • Stage T3b/T4 disease or radiological or pathological pelvic nodal metastases
• • Localized disease (stage pT2-T4) with \> 30% estimated risk of pelvic nodal metastases
• • High-risk (Gleason score ≥ 8 or ≥ 2 risk factors) or very high-risk disease according to the National Collaborative Cancer Network (NCCN)
• • Has undergone prostatectomy AND has stage T2-T3a, N0 disease with extensive high-risk disease (Gleason score ≥ 8) or seminal vesicle or lymph node involvement
• • Candidate for radical radiotherapy
• PATIENT CHARACTERISTICS:
• • No inflammatory bowel disease or other small bowel disease
• PRIOR CONCURRENT THERAPY:
• • No prior pelvic radiotherapy or surgery (excluding prostatectomy)